Subscribe To
SLDB / Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial
SLDB News
By GlobeNewsWire
May 8, 2023
Solid Biosciences to Present at JMP Securities Life Sciences Conference
CHARLESTOWN, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for n more_horizontal
By GlobeNewsWire
January 9, 2023
Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for ne more_horizontal
By Seeking Alpha
April 30, 2022
Solid Biosciences Inc. (SLDB) CEO Ilan Ganot on Q1 2022 Results - Earnings Call Transcript
Solid Biosciences Inc. (NASDAQ:SLDB ) Q1 2022 Results Conference Call April 27, 2022 8:00 AM ET Company Participants Caitlin Lowie - VP, Communication more_horizontal
By Benzinga
March 14, 2022
Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial
Solid Biosciences Inc (NASDAQ: SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in t more_horizontal